Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer
Background The aim of our study was to retrospectively assess the incidence of interstitial lung disease (ILD) related to EGFR‐tyrosine kinase inhibitor (TKI) treatment immediately before and/or after the administration of a PD‐1 antibody. Methods We analyzed the data of 26 patients who underwent tr...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-04-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.13039 |
| _version_ | 1827965848518656000 |
|---|---|
| author | Takahiro Uchida Kyoichi Kaira Ou Yamaguchi Atsuto Mouri Ayako Shiono Yu Miura Kosuke Hashimoto Fuyumi Nishihara Yoshitake Murayama Kunihiko Kobayashi Hiroshi Kagamu |
| author_facet | Takahiro Uchida Kyoichi Kaira Ou Yamaguchi Atsuto Mouri Ayako Shiono Yu Miura Kosuke Hashimoto Fuyumi Nishihara Yoshitake Murayama Kunihiko Kobayashi Hiroshi Kagamu |
| author_sort | Takahiro Uchida |
| collection | DOAJ |
| description | Background The aim of our study was to retrospectively assess the incidence of interstitial lung disease (ILD) related to EGFR‐tyrosine kinase inhibitor (TKI) treatment immediately before and/or after the administration of a PD‐1 antibody. Methods We analyzed the data of 26 patients who underwent treatment with EGFR‐TKIs immediately before and/or after the administration of an anti‐PD‐1 antibody. Results Four out of the 26 patients developed ILD during EGFR‐TKI treatment: three patients during the administration of osimertinib immediately after, and one during afatinib immediately before treatment with an anti‐PD‐1 antibody. Three of 12 patients who underwent EGFR‐TKI therapy immediately after anti‐PD‐1 antibody treatment experienced osimertinib‐induced ILD. ILD was not observed in the five patients administered an anti‐PD‐1 antibody followed by first or second‐generation EGFR‐TKIs. Conclusion ILD was observed in the treatment sequence of an anti‐PD‐1 antibody followed by osimertinib, but not with first or second‐generation EGFR‐TKIs. |
| first_indexed | 2024-04-09T17:39:52Z |
| format | Article |
| id | doaj.art-ad66614d07bc4339814a5f860205d0da |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-04-09T17:39:52Z |
| publishDate | 2019-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-ad66614d07bc4339814a5f860205d0da2023-04-17T06:34:28ZengWileyThoracic Cancer1759-77061759-77142019-04-0110497597910.1111/1759-7714.13039Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancerTakahiro Uchida0Kyoichi Kaira1Ou Yamaguchi2Atsuto Mouri3Ayako Shiono4Yu Miura5Kosuke Hashimoto6Fuyumi Nishihara7Yoshitake Murayama8Kunihiko Kobayashi9Hiroshi Kagamu10Department of Respiratory Medicine Comprehensive Cancer Center, International Medical Center Saitama Medical University Saitama JapanDepartment of Respiratory Medicine Comprehensive Cancer Center, International Medical Center Saitama Medical University Saitama JapanDepartment of Respiratory Medicine Comprehensive Cancer Center, International Medical Center Saitama Medical University Saitama JapanDepartment of Respiratory Medicine Comprehensive Cancer Center, International Medical Center Saitama Medical University Saitama JapanDepartment of Respiratory Medicine Comprehensive Cancer Center, International Medical Center Saitama Medical University Saitama JapanDepartment of Respiratory Medicine Comprehensive Cancer Center, International Medical Center Saitama Medical University Saitama JapanDepartment of Respiratory Medicine Comprehensive Cancer Center, International Medical Center Saitama Medical University Saitama JapanDepartment of Respiratory Medicine Comprehensive Cancer Center, International Medical Center Saitama Medical University Saitama JapanDepartment of Respiratory Medicine Comprehensive Cancer Center, International Medical Center Saitama Medical University Saitama JapanDepartment of Respiratory Medicine Comprehensive Cancer Center, International Medical Center Saitama Medical University Saitama JapanDepartment of Respiratory Medicine Comprehensive Cancer Center, International Medical Center Saitama Medical University Saitama JapanBackground The aim of our study was to retrospectively assess the incidence of interstitial lung disease (ILD) related to EGFR‐tyrosine kinase inhibitor (TKI) treatment immediately before and/or after the administration of a PD‐1 antibody. Methods We analyzed the data of 26 patients who underwent treatment with EGFR‐TKIs immediately before and/or after the administration of an anti‐PD‐1 antibody. Results Four out of the 26 patients developed ILD during EGFR‐TKI treatment: three patients during the administration of osimertinib immediately after, and one during afatinib immediately before treatment with an anti‐PD‐1 antibody. Three of 12 patients who underwent EGFR‐TKI therapy immediately after anti‐PD‐1 antibody treatment experienced osimertinib‐induced ILD. ILD was not observed in the five patients administered an anti‐PD‐1 antibody followed by first or second‐generation EGFR‐TKIs. Conclusion ILD was observed in the treatment sequence of an anti‐PD‐1 antibody followed by osimertinib, but not with first or second‐generation EGFR‐TKIs.https://doi.org/10.1111/1759-7714.13039AfatinibEGFR‐TKIILDnivolumabosimertinib |
| spellingShingle | Takahiro Uchida Kyoichi Kaira Ou Yamaguchi Atsuto Mouri Ayako Shiono Yu Miura Kosuke Hashimoto Fuyumi Nishihara Yoshitake Murayama Kunihiko Kobayashi Hiroshi Kagamu Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer Thoracic Cancer Afatinib EGFR‐TKI ILD nivolumab osimertinib |
| title | Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer |
| title_full | Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer |
| title_fullStr | Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer |
| title_full_unstemmed | Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer |
| title_short | Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer |
| title_sort | different incidence of interstitial lung disease according to different kinds of egfr tyrosine kinase inhibitors administered immediately before and or after anti pd 1 antibodies in lung cancer |
| topic | Afatinib EGFR‐TKI ILD nivolumab osimertinib |
| url | https://doi.org/10.1111/1759-7714.13039 |
| work_keys_str_mv | AT takahirouchida differentincidenceofinterstitiallungdiseaseaccordingtodifferentkindsofegfrtyrosinekinaseinhibitorsadministeredimmediatelybeforeandorafterantipd1antibodiesinlungcancer AT kyoichikaira differentincidenceofinterstitiallungdiseaseaccordingtodifferentkindsofegfrtyrosinekinaseinhibitorsadministeredimmediatelybeforeandorafterantipd1antibodiesinlungcancer AT ouyamaguchi differentincidenceofinterstitiallungdiseaseaccordingtodifferentkindsofegfrtyrosinekinaseinhibitorsadministeredimmediatelybeforeandorafterantipd1antibodiesinlungcancer AT atsutomouri differentincidenceofinterstitiallungdiseaseaccordingtodifferentkindsofegfrtyrosinekinaseinhibitorsadministeredimmediatelybeforeandorafterantipd1antibodiesinlungcancer AT ayakoshiono differentincidenceofinterstitiallungdiseaseaccordingtodifferentkindsofegfrtyrosinekinaseinhibitorsadministeredimmediatelybeforeandorafterantipd1antibodiesinlungcancer AT yumiura differentincidenceofinterstitiallungdiseaseaccordingtodifferentkindsofegfrtyrosinekinaseinhibitorsadministeredimmediatelybeforeandorafterantipd1antibodiesinlungcancer AT kosukehashimoto differentincidenceofinterstitiallungdiseaseaccordingtodifferentkindsofegfrtyrosinekinaseinhibitorsadministeredimmediatelybeforeandorafterantipd1antibodiesinlungcancer AT fuyuminishihara differentincidenceofinterstitiallungdiseaseaccordingtodifferentkindsofegfrtyrosinekinaseinhibitorsadministeredimmediatelybeforeandorafterantipd1antibodiesinlungcancer AT yoshitakemurayama differentincidenceofinterstitiallungdiseaseaccordingtodifferentkindsofegfrtyrosinekinaseinhibitorsadministeredimmediatelybeforeandorafterantipd1antibodiesinlungcancer AT kunihikokobayashi differentincidenceofinterstitiallungdiseaseaccordingtodifferentkindsofegfrtyrosinekinaseinhibitorsadministeredimmediatelybeforeandorafterantipd1antibodiesinlungcancer AT hiroshikagamu differentincidenceofinterstitiallungdiseaseaccordingtodifferentkindsofegfrtyrosinekinaseinhibitorsadministeredimmediatelybeforeandorafterantipd1antibodiesinlungcancer |